Publications by authors named "P Royer"
Article Synopsis
- Recent research tested a new treatment called LIS1, derived from genetically modified pigs, to see if it could safely be used in kidney transplant patients instead of traditional rabbit-derived antithymocyte globulins (ATGs).
- The study showed that LIS1 effectively depleted T cells without causing major side effects, such as cytokine release syndrome, and was well tolerated by patients.
- Results indicated that LIS1 has a long half-life and allows for quick recovery of lymphocyte counts, suggesting it could be a promising alternative for transplant immunosuppression.
Article Synopsis
- XAV-19 is a targeted swine polyclonal antibody for SARS-CoV-2 that was tested for safety and effectiveness in patients with mild to moderate COVID-19 in a clinical trial.
- The trial was a phase II/III, double-blind, placebo-controlled study involving 279 patients where the primary focus was on whether XAV-19 could prevent disease worsening within eight days of treatment.
- Results indicated that while there were no significant differences in the primary endpoint, XAV-19 accelerated recovery times, particularly for patients with lower severity scores, and demonstrated effective neutralization against various COVID-19 variants.
Aims: Improved identification of individuals at high risk of developing cardiovascular disease would enable targeted interventions and potentially lead to reductions in mortality and morbidity. Our aim was to determine whether use of large-scale proteomics improves prediction of cardiovascular events beyond traditional risk factors (TRFs).
Methods And Results: Using proximity extension assays, 2919 plasma proteins were measured in 38 380 participants of the UK Biobank.
Introduction: In case of pneumonia, some biological findings are suggestive for Legionnaire's disease (LD) including C-reactive protein (CRP). A low level of CRP is predictive for negative Legionella Urinary-Antigen-Test (L-UAT).
Method: Observational retrospective study in Nord-Franche-Comté Hospital with external validation in Besançon University Hospital, France which included all adults with L-UAT performed during January 2018 to December 2022.
Article Synopsis
- Polyclonal rabbit antithymocyte globulins (ATGs) used in organ transplants can cause unwanted inflammation, while LIS1, a new generation of antilymphocyte globulins derived from genetically modified pigs, aims to reduce these risks.
- A phase 1 study tested LIS1 in kidney transplant patients to assess its safety, T cell depletion effects, and pharmacokinetics.
- Results indicated that LIS1 was well tolerated, effectively depleted T cells in certain dosage groups, and did not provoke severe side effects or the formation of antidrug antibodies.